Acadia Pharma terminates COO Brendan Teehan without cause; CEO assumes duties

ACADIA PHARMACEUTICALS INC

Brendan Teehan, EVP, COO and Head of Commercial, involuntarily terminated without Cause effective Nov 18, 2024.
Teehan will remain a non-executive employee until Dec 31, 2024 to assist transition.
CEO Catherine Owen Adams, with 30+ years pharma commercial experience, will assume his responsibilities until a successor is appointed.
No successor has been named; search for replacement is underway.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brendan Teehan

Executive Vice President, Chief Operating Officer and Head of Commercial

ACAD · ACADIA PHARMACEUTICALS INC

Effective: 2024-11-18
Filed: November 20, 2024, 6:59 PM ET

On November 18, 2024, Acadia Pharmaceuticals Inc. (the “Company”) agreed with Brendan Teehan, Executive Vice President, Chief Operating Officer and Head of Commercial that he would be involuntarily terminated without Cause (as such term is defined in the Company’s Management Severance Benefit Plan (the “Severance Plan”)) from his position, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brendan Teehan departed as Executive Vice President, Chief Operating Officer and Head of Commercial at ACADIA PHARMACEUTICALS INC.

Action: involuntarily terminated without Cause
Role: Executive Vice President, Chief Operating Officer and Head of Commercial

Exact text from the filing

On November 18, 2024, Acadia Pharmaceuticals Inc. (the “Company”) agreed with Brendan Teehan, Executive Vice President, Chief Operating Officer and Head of Commercial that he would be involuntarily terminated without Cause (as such term is defined in the Company’s Management Severance Benefit Plan (the “Severance Plan”)) from his position, effective immediately.

View on SEC.gov

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-24-262556

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.